Titusville: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved CAPLYTA (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.

This approval marks the fourth indication for CAPLYTA, an FDA-approved treatment for bipolar I and II depression in adults, as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults.

MDD, or clinical depression, is one of the most common psychiatric disorders, affecting about 22 million American adults. While oral antidepressants may offer relief for some, 2 in 3 people living with MDD continue to experience residual symptoms despite treatment, significantly impacting their overall quality of life. Beyond its toll

See Full Page